




Article

ALK inhibitors-induced M phase delay contributes to the suppression of cell proliferation

Sirajam Munira, Ryuzaburo Yuki, Youhei Saito and Yuji Nakayama

Supplementary Materials






Figure S1. Detection of ALK protein expression in ALK-positive and negative cells. **(A)** Cell lysates were prepared from indicated cells and examined by Western blotting with anti-pALK-Y1507, anti-ALK, and anti-lamin B (loading control) antibodies. Asterisk indicates non-specific bands. **(B)** MCF7

Cancers 2020, 12, x 2 of 8

and SH-SY5Y cells were transfected with total 60 pmol of three ALK-targeting siRNAs (siALK #1-3) or nontargeting siRNA (siCtrl). At 70 h after transfection, whole cell lysates were prepared and analyzed by Western blotting with anti-ALK and anti-lamin B (loading control) antibodies. The band intensities were measured and their ratios to that in SH-SY5Y (upper panel) or siCtrl-treated cells (lower panel) are shown below the blots.




Figure S2. Effect of c-Met inhibition on M-phase progression. **(A)** Whole cell lysates were examined by Western blotting with anti-Met and anti-actin (loading control) antibodies. **(B)** HeLa S3 cells were synchronized with 6 μM RO-3306. After release from RO-3306, HeLa S3 cells were incubated with 1 μM crizotinib for 1 h. As described in Figure 1C, cells were divided into four groups. The percentages of cells of each group (n > 253 in each experiment) and mitotic indices (n > 476 in each experiment) are plotted as the mean \pm SD calculated from three independent experiments. HeLa S3 cells were treated with c-Met-targeting siRNA and nontargeting siCtrl. **(C)** At 28 h after transfection, cells were synchronized with RO-3306 and released in fresh media for 60 min. M phase cells were classified into two groups: before (P/PM/M) and after (A/T/Cyto) anaphase onset. Percentages of cells (n > 247 in each experiment) and mitotic indices (n > 507 in each experiment) are plotted as the mean \pm SD calculated from three independent experiments. Student's t-test and the Tukey–Kramer multiple comparison test were used to calculate p values. **p < 0.01, N.S., not significant. **(D)** After 48 h of transfection, whole cell lysates were examined by Western blotting with indicated antibodies.

Cancers 2020, 12, x 3 of 8




Figure S3. Time-lapse images of Figure 2 in short interval of time are shown. Scale bar, 10 μm

Cancers 2020, 12, x 4 of 8






Figure S4. Inducible expression of ALK-HA in Dox-treated cells. SH-SY5Y/ALK-HA cells were transfected with 3'-UTR-targeting siALK (siALK #3) for 72 h with or without Dox. Microscopic images were taken at $10\times$ objective. Scale bar, $20~\mu m$.

Cancers 2020, 12, x 5 of 8




Full-length blots of Figure 1A.




Full-length blots of Figure 1E.

Figure S5. Full-length blots of Figure 1. The band intensities were measured and their ratios to that in SH-SY5Y (upper panel) or DMSO-treated cells (lower panel) are shown below the blots. Asterisk indicates non-specific bands.

Cancers 2020, 12, x 6 of 8




Full-length blots of Figure 3A.



Full-length blots of Figure 3D.

Figure S6. Full-length blots of Figure 3. The band intensities were measured and their ratios to that in siCtrl-treated cells are shown below the blots.


Cancers 2020, 12, x 7 of 8




Full-length blots of Figure 6B.

Figure S7. Full-length blots of Figure 6. The band intensities were measured and their ratios to that in DMSO-treated cells are shown below the blots. Asterisks indicate non-specific bands.

Cancers 2020, 12, x 8 of 8



Full-length blots of Supplementary Figure S2A.



Full-length blots of Supplementary Figure S2D.

Figure S8. Full-length blots of Figure S2. The band intensities were measured and their ratios to that in HeLa S3 (upper panel) or siCtrl-treated cells (lower panel).



@ 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).